Effectiveness of Infliximab in the Treatment of Refractory Perineal Cutaneous Crohn Disease

Hidradenitis Suppurativa and Crohn's Disease: Response to Treatment with Infliximab

“…Perianal CD, noncontiguous with the involvement of the gastrointestinal tract, is regarded by some as metastatic CD. There is a report of one case of refractory perineal cutaneous CD treated successfully with anti-TNF (14).…”

Refractory ulcers: The role of tumor necrosis factor–α

“…In addition, the Food and Drug Administration approved infliximab, adalimumab, and certolizumab for the treatment of Crohn's disease. Infliximab has been shown to be effective for several inflammatory dermatological conditions, including psoriasis, 91,92 subcorneal pustular dermatosis, 93 hidradenitis suppurativa, 94 acute graft-versus-host disease, 95 Behçet's disease, 96,97 refractory sarcoidosis, 98 orofacial and perineal cutaneous Crohn's disease, 99,100 pityriasis rubra pilaris, and necrobiosis lipoidica. 101 Etanercept (Enbrel) is a human fusion protein of the receptor TNF-Rp75 and the Fc part of IgG1.…”

Use of Infliximab, an Anti-Tumor Necrosis Alpha Antibody, for Inflammatory Dermatoses

“…6,7 Moreover, case reports and/or small series of successful treatment of patients with pyoderma gangrenosum, 8,9 Behçet's disease, 10,11 refractory sarcoidosis, 12 and orofacial and perineal cutaneous Crohn's disease 13,14 have been published. In these cases, the patients received intravenous infliximab 5-10 mg/kg for their refractory disease, which had been nonresponsive to previous treatments.…”